5 Reports on Lymphoma Patients May Have Missed

Ryan McDonald
Ryan McDonald

Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at rmcdonald@curetoday.com.

CURE® compiled a roundup of five recent reports patients with lymphoma may have missed.

CURE® presents the following reports on the most recent updates and developments in lymphoma that patients may have missed.

These reports include research of a novel CAR-T cell therapy in advanced Hodgkin lymphoma, as well an updated analysis of breast-implant associated lymphoma.

  • Enzastaurin (DB102) may be associated with an increased benefit in patients with diffuse large B-cell lymphoma (DLBCL) with a Denovo Genomic Marker 1 (DGM1) biomarker, according to Dr. Grzegorz S. Nowakowski.
  • There have now been 733 unique cases of breast-implant associated anaplastic large cell lymphoma and 36 deaths reported to the Food and Drug Administration, which is an increase of 160 new cases and three deaths since the most recent report in July 2019.
  • In patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, low muscle mass (LMM) and low muscle density (LMD) could play a role when deciding what kind of treatment option to pursue, and could also impact a patient’s odds of survival.
  • Use of a novel anti-CD30 CAR T-cell therapy following treatment with fludarabine-based lymphodepletion induced a high rate of durable responses in patients with heavily pretreated relapsed or refractory Hodgkin lymphoma.
  • Patients with relapsed or refractory follicular lymphoma treated with Kymriah (tisagenlecleucel) – a CAR-T cell therapy – achieved a target complete response rate, according to an interim analysis of the phase 2 ELARA trial.